Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for
potentially curable neoplasms such as acute lymphoblastic leukemia. In multiple myeloma …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow,
leading to bone destruction and marrow failure. This manuscript discusses the management …

In the past decade, one of the major advances in the management of patients with
symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents …

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These
neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone …

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis,
workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy …

Multiple myeloma management has undergone profound changes in the past thanks to
advances in our understanding of the disease biology and improvements in treatment and …

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis,
evaluation, treatment, including supportive-care, and follow-up for patients with myeloma …

Recent developments have led to remarkable improvements in the assessment and
treatment of patients with multiple myeloma (MM). New technologies have become available …